NASDAQ:NXTC NextCure Q2 2023 Earnings Results & Report $5.67 -0.57 (-9.13%) Closing price 10/19/2026 04:00 PM EasternExtended Trading$5.68 +0.01 (+0.18%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NextCure missed analyst earnings expectations in its Q2 2023 results, released August 3, 2023. The company reported EPS of -$7.68 versus the -$7.20 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2023Report DateAugust 3, 2023Conference Call4:00 PM ET NextCure EPS ResultsActual EPS-$7.68Consensus EPS -$7.20Beat/MissMissed by -$0.48One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNextCure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNextCure's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NextCure Q2 2023 Earnings FAQ Did NextCure beat earnings estimates for Q2 2023? NextCure (NASDAQ:NXTC) reported earnings of -$7.68 per share for Q2 2023, missing the consensus estimate of -$7.20. The report was announced on Thursday, August 3, 2023. When is NextCure's next earnings date? NextCure's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for NextCure on the company's earnings history page. NextCure Earnings HeadlinesNextCure Faces Court Review of Reverse Stock SplitSeptember 28, 2026 | theglobeandmail.comNextCure Ends Beltsville Lease to Cut Operating CostsSeptember 3, 2026 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001August 10, 2026 | prnewswire.comNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | markets.businessinsider.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHBJuly 23, 2026 | globenewswire.comSee More NextCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email. Email Address About NextCureNextCure (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company’s research is centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack tumor cells, with the goal of addressing limitations associated with existing cancer immunotherapies. NextCure’s pipeline has included investigational antibody-based therapies and other immune-modulating programs targeting mechanisms that can suppress immune responses in the tumor microenvironment. Its lead programs have been evaluated in clinical studies involving patients with advanced solid tumors, including as standalone treatments and in combination with other anticancer therapies. Founded in 2015 and headquartered in the United States, NextCure has advanced its programs through early-stage clinical development and has conducted research and clinical activities in collaboration with healthcare and pharmaceutical organizations. As a development-stage biotechnology company, its products remain investigational and are subject to clinical, regulatory, and commercial uncertainties.View NextCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Tesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Meta Claims Frontier-Class AI Status With New Muse Wonder Models Upcoming Earnings Meta Platforms (10/21/2026)AT&T (10/21/2026)Tesla (10/21/2026)Philip Morris International (10/21/2026)Kinder Morgan (10/21/2026)CME Group (10/21/2026)Moody's (10/21/2026)Abbott Laboratories (10/21/2026)Danaher (10/21/2026)Elevance Health (10/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
